JP2016529228A5 - - Google Patents

Download PDF

Info

Publication number
JP2016529228A5
JP2016529228A5 JP2016525422A JP2016525422A JP2016529228A5 JP 2016529228 A5 JP2016529228 A5 JP 2016529228A5 JP 2016525422 A JP2016525422 A JP 2016525422A JP 2016525422 A JP2016525422 A JP 2016525422A JP 2016529228 A5 JP2016529228 A5 JP 2016529228A5
Authority
JP
Japan
Prior art keywords
compound
hypotension
group
disorder
isotopically enriched
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016525422A
Other languages
English (en)
Japanese (ja)
Other versions
JP6567515B2 (ja
JP2016529228A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/045731 external-priority patent/WO2015006315A1/en
Publication of JP2016529228A publication Critical patent/JP2016529228A/ja
Publication of JP2016529228A5 publication Critical patent/JP2016529228A5/ja
Application granted granted Critical
Publication of JP6567515B2 publication Critical patent/JP6567515B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016525422A 2013-07-08 2014-07-08 ジヒドロキシフェニル神経伝達物質の化合物、組成物、および方法 Expired - Fee Related JP6567515B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361843549P 2013-07-08 2013-07-08
US61/843,549 2013-07-08
US201462010098P 2014-06-10 2014-06-10
US62/010,098 2014-06-10
PCT/US2014/045731 WO2015006315A1 (en) 2013-07-08 2014-07-08 Dihydroxyphenyl neurotransmitter compounds, compositions and methods

Publications (3)

Publication Number Publication Date
JP2016529228A JP2016529228A (ja) 2016-09-23
JP2016529228A5 true JP2016529228A5 (enExample) 2017-06-29
JP6567515B2 JP6567515B2 (ja) 2019-08-28

Family

ID=52133230

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016525422A Expired - Fee Related JP6567515B2 (ja) 2013-07-08 2014-07-08 ジヒドロキシフェニル神経伝達物質の化合物、組成物、および方法

Country Status (16)

Country Link
US (5) US20150011630A1 (enExample)
EP (2) EP3019467A4 (enExample)
JP (1) JP6567515B2 (enExample)
KR (1) KR20160041912A (enExample)
CN (1) CN105473545B (enExample)
AU (2) AU2014287418A1 (enExample)
BR (1) BR112016000338A8 (enExample)
CA (1) CA2917159C (enExample)
CL (1) CL2016000019A1 (enExample)
EA (1) EA201600093A1 (enExample)
HK (1) HK1221713A1 (enExample)
IL (2) IL243488A0 (enExample)
MX (1) MX384131B (enExample)
PE (1) PE20160556A1 (enExample)
SG (2) SG10201800166UA (enExample)
WO (1) WO2015006315A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3032168C (en) * 2016-08-30 2020-04-21 Theravance Biopharma R&D Ip, Llc Compound for use in the treatment of neurogenic orthostatic hypotension
GB2566516A (en) 2017-09-15 2019-03-20 Univ Oxford Innovation Ltd Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
CA3130291A1 (en) 2019-03-27 2020-10-01 Anthony P. FORD Beta adrenergic agonist and methods of using the same
US12377112B2 (en) 2019-04-17 2025-08-05 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
US20220401415A1 (en) * 2019-10-25 2022-12-22 Curasen Therapeutics, Inc. Methods for treating neurological disorders with alpha1a-ar partial agonists
US11607395B2 (en) 2019-12-18 2023-03-21 Curasen Therapeutics, Inc. Methods for improving neurological diseases and disorders
WO2021247963A1 (en) * 2020-06-05 2021-12-09 Senda Biosciences, Inc. (s)-alpha-fluoromethyltyrosine as decarboxylase inhibitors for use in the treatment of hypotension

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3360726D1 (en) 1982-01-14 1985-10-17 Sumitomo Chemical Co Process for producing threo-3-(3,4-dihydroxyphenyl)serine
CA1223602A (en) 1983-05-25 1987-06-30 Naohito Ohashi Process for producing 3-(3,4-dihydroxyphenyl) serine
JP3764179B2 (ja) 1994-07-05 2006-04-05 克寛 西野 運動・意識または言語障害の機能改善剤
DE19619510A1 (de) 1995-05-18 1996-11-21 Sumitomo Chemical Co Verfahren zur Herstellung von Threo-3-(3,4-dihydroxyphenyl)serin
JP3489319B2 (ja) 1996-03-12 2004-01-19 住友化学工業株式会社 カルボン酸誘導体、その製造法および用途
JPH115738A (ja) 1997-06-15 1999-01-12 Katsuhiro Nishino 脳虚血に伴う神経脱落症状の予防剤および超急性期治療剤
US6376531B1 (en) * 1998-11-13 2002-04-23 Rupert Charles Bell Method of treatment using deuterium compounds
DE10261807A1 (de) 2002-12-19 2004-07-01 Turicum Drug Development Ag Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel
WO2005084330A2 (en) 2004-03-02 2005-09-15 Synergia Pharma, Inc. Compositions and methods for treating nasal congestion
HUE028777T2 (en) * 2006-02-17 2017-01-30 Ratiopharm Gmbh Deuterated catecholamine derivatives and medicaments containing these compounds
US8008285B2 (en) 2007-03-09 2011-08-30 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia
EP2142185B1 (en) * 2007-03-12 2012-08-15 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension
AU2008248382B2 (en) 2007-05-07 2013-07-18 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
WO2008151179A2 (en) 2007-06-04 2008-12-11 Auspex Pharmaceuticals, Inc. Substituted phenethylamines
US20100172916A1 (en) * 2008-11-10 2010-07-08 Auspex Pharmaceuticals, Inc. Substituted hydroxyphenylamine compounds
WO2010132128A1 (en) 2009-05-14 2010-11-18 The Board Of Trustees Of The Leland Stanford Junior University Method of improving cognitve functions in individuals with down syndrome and/or alzheimer's disease
CN102548957A (zh) 2009-07-01 2012-07-04 大日本住友制药株式会社 制备苏-3-(3，4-二羟基苯基)-l-丝氨酸的方法
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤
US20130253061A1 (en) 2012-03-20 2013-09-26 Chelsea Therapeutics, Inc. Method of droxidopa synthesis

Similar Documents

Publication Publication Date Title
JP2016529228A5 (enExample)
JP2012503010A5 (enExample)
JP2010507585A5 (enExample)
JP2009539863A5 (enExample)
JP2009538359A5 (enExample)
CA2917159C (en) Dihydroxyphenyl neurotransmitter compounds, compositions and methods
JP2009527462A5 (enExample)
US20100087455A1 (en) Substituted xanthine compounds
US20200078346A1 (en) Combination of pimavanserin and cytochrome p450 modulators
JP2012526791A5 (enExample)
US20100172916A1 (en) Substituted hydroxyphenylamine compounds
US20180016244A1 (en) Deuterium-substituted oxadiazoles
JP2010512343A5 (enExample)
US10953000B2 (en) Combination of pimavanserin and cytochrome P450 modulators
US20190047951A1 (en) Azetidine modulators of the sphingosine 1-phosphate receptor
CA2631581A1 (en) Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
US20220062268A1 (en) Pharmaceutical composition for the treatment of parkinson's disease
US20100075950A1 (en) Phenylpropanone modulators of dopamine receptor
JP2018507210A5 (enExample)
US20100286124A1 (en) Prop-2-yn-1-amine inhibitors of monoamine oxidase type b
RU2024129873A (ru) Дейтерированные аналоги пиррольных ингибиторов erk, их синтез и промежуточные соединения
JP2013516490A5 (enExample)
HK40022683A (en) Dihydroxyphenyl neurotransmitter compounds, compositions and methods
HK1216747B (en) Dihydroxyphenyl neurotransmitter compounds, compositions and methods